Hard to know when and what might re-rate the SP? Nothing wrong with the progress IMO. Downside from recent announcement might be what percentage revenue AXE might get on the deal? Overall there’s far more positives in clarifying path to market and resources needed to get a biochip to market. Perhaps something to look at from time to time and not be focussed on short term SP, disappointing as it might be for a while.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $76.45M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 31.0¢ | 29.0¢ | $89.91K | 296.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4600 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 5155 | 1 |
View Market Depth
| Last trade - 16.10pm 28/07/2025 (20 minute delay) ? |
| AXE (ASX) Chart |